Clinical Cell Culture Limited Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Clinical Cell Culture Limited's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Contents

• 1 List of Tables
  • 1.2 List of Figures
• 2 Company Snapshot
  • 2.1 Key Information
  • 2.2 Company Overview
• 3 Business Description
  • 3.1 Business Overview
  • 3.2 Major Products and Services
    • 3.2.1 Overview
• 4 History
• 5 Competitors
• 6 Key Employees
• 7 Key Employee Biographies
• 8 Company Statement
• 9 Locations And Subsidiaries
  • 9.1 Head Office
  • 9.2 Other Locations & Subsidiaries
• 10 Recent Developments
  • 10.1 Financial Announcements
    • 10.1.1 Aug 31, 2007: C3 Declares Fiscal 2007 Results
    • 10.1.2 Feb 27, 2007: C3 Declares H1 2007 Results
    • 10.1.3 Sep 07, 2006: C3 Declares Fiscal 2006 Results
  • 10.2 Corporate Communications
    • 10.2.1 Feb 15, 2008: C3 Directors Resigns
  • 10.3 Product News
    • 10.3.1 Aug 07, 2008: Avita Signs Greek Distribution Deal
    • 10.3.2 Jul 21, 2008: Chinese SFDA Approves Helicon Group's ReCell Concept And Kit
    • 10.3.3 Jul 03, 2008: Avita ReCell Product Approved In China
    • 10.3.4 Dec 15, 2006: Recell Approved In Brazil And Turkey
    • 10.3.5 Nov 27, 2006: Update On US Regulatory Approval For Recell
    • 10.3.6 Nov 14, 2006: Recell Clinical Update
    • 10.3.7 Nov 08, 2006: Cellspray Approved In Greece
    • 10.3.8 Sep 28, 2006: Clinical Cell Culture Announces CSL Supply Agreement
    • 10.3.9 Jun 27, 2006: Recell Approved In Canada
    • 10.3.10 May 25, 2006: TGA Approves Recell
    • 10.3.11 Apr 03, 2006: TGA Recommends Recell For Approval
    • 10.3.12 Jan 16, 2006: Regulatory Update On Recell FDA And TGA
  • 10.4 Product Approvals
    • 10.4.1 Jul 21, 2008: Chinese SFDA Approves Helicon Group's ReCell Concept And Kit
    • 10.4.2 Jul 03, 2008: Avita ReCell Product Approved In China
    • 10.4.3 Dec 15, 2006: Recell Approved In Brazil And Turkey
    • 10.4.4 Nov 08, 2006: Cellspray Approved In Greece
    • 10.4.5 Jun 27, 2006: Recell Approved In Canada
    • 10.4.6 May 25, 2006: TGA Approves Recell
  • 10.5 Clinical Trials
    • 10.5.1 Nov 14, 2006: Recell Clinical Update
  • 10.6 Other Significant Developments
    • 10.6.1 May 06, 2008: C3 Proposes Name Change
• 11 Clinical Cell Culture Limited Pipeline Products
  • 11.1 Clinical Cell Culture Limited Product Pipeline Analysis
    • 11.1.1 Clinical Cell Culture Limited Pipeline Products By Equipment Type
    • 11.1.2 Clinical Cell Culture Limited Pipeline Products By Development Stage
    • 11.1.3 Clinical Cell Culture Limited Pipeline Products By Therapy Area
    • 11.1.4 Clinical Cell Culture Limited Pipeline Products By News Summary
  • 11.2 Cell Delivery Device (CDD)
    • 11.2.1 Product Description
    • 11.2.2 Product Status
  • 11.3 ReCell
    • 11.3.1 Product Description
    • 11.3.2 Product Status
    • 11.3.3 Product Milestone
  • 11.4 CellSpray
    • 11.4.1 Product Description
    • 11.4.2 Product Status
    • 11.4.3 Product Milestone
  • 11.5 CellSpray XP
    • 11.5.1 Product Description
    • 11.5.2 Product Status
• 12 Appendix
  • 12.1 Methodology
    • 12.1.1 Coverage
    • 12.1.2 Secondary Research
    • 12.1.3 Primary Research
    • 12.1.4 Expert Panel Validation
  • 12.2 Contact Us
  • 12.3 About Global Markets Direct
  • 12.4 Disclaimer
• 1 List of Tables
  • Table 1: Clinical Cell Culture Limited,Key Facts
  • Table 2: Clinical Cell Culture Limited, Key Employees,
  • Table 3: Clinical Cell Culture Limited, Subsidiaries
  • Table 4: Clinical Cell Culture Limited Pipeline Products by Equipment Type
  • Table 5: Clinical Cell Culture Limited Pipeline Products By Development Stage
  • Table 6: Clinical Cell Culture Limited Pipeline Products By Therapy Area
  • Table 7: Clinical Cell Culture Limited Pipeline Products By News Summaries
  • 1.2 List of Figures
  • Figure 1: Clinical Cell Culture Limited Pipeline Products By Development Stage
  • Figure 2: Clinical Cell Culture Limited Pipeline Products By News Summary
  • Figure 3: Global Markets Direct Methodology